Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.

---

McDonald A. B., Verburgh E., Gotti M., Pinto A., Zaucha J., Ivanov V., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.41, sa.16, 2023 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Özet
• Cilt numarası: 41 Sayı: 16
• Basım Tarihi: 2023
• Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, CINAHL, Gender Studies Database, International Pharmaceutical Abstracts, Veterinary Science Database
• Ankara Üniversitesi Adresli: Evet